Form 4/A for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-09-22 00:00:00 ET · period of report 2022-09-16 · accession 0000886163-22-000125 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-09-22 | 2022-09-16 | LGND | HIGGINS JOHN L | CEO, Dir | S - Sale | $88.06 | -1,000 | 366.2K | -0.3% | -$88.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-16 | S | D | 1,000 | $88.06 | 366,180 | D | — | — | (F1) On September 16, 2022, due to an issue with the equity administration system of the company, the reporting person filed a Form 4 which inadvertently reported the sale of a higher number of shares than were actually sold by the reporting person. The correct number of shares sold is listed above. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.05 to $88.12, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |